Johnson & Johnson

Johnson & Johnson on fru.dev

• Frontier tech

Johnson & Johnson across fru.dev: timeline

1. 2026-03-30 First randomized Phase 2 data for JNJ-1900 in stage 3 lung cancer (Emerging)
2. 2025-07-07 European regulators reclassify NBTXR3 from device to medicinal product (Emerging)
3. 2025-03-17 Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnson (Emerging)

Sources

• emerging.fru.dev/companies/johnson-and-johnson